Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 6561-6570 Newer>

The Motley Fool August 11, 2010 Charly Travers	Insiders Are Buying Quidel. Should You? Does insider buying and a cheap price make for a good buy?
The Motley Fool August 11, 2010 Brian Orelli	Dang! This Drug Is Shining Brighter Vertex illuminates telaprevir's additional benefit in treating hepatitis C patients.
The Motley Fool August 11, 2010 Seth Jayson	Marginal Performance at Affymetrix Here's the current margin snapshot for Affymetrix and some of its sector and industry peers, and direct competitors.
The Motley Fool August 11, 2010 David Meier	Kimball International: Deflation Fighter Compared to competitors Herman Miller and HNI Corp., Kimball International is better prepared to handle a deflationary environment.
The Motley Fool August 11, 2010 David Meier	Is Bruker's Management Up to the Task? Bruker has generated those impressive returns while vying with Danaher and PerkinElmer. That impressive achievement suggests that management knows what it's doing.
The Motley Fool August 11, 2010 David Meier	Does Bill Miller Think Johnson & Johnson Is Attractive? Johnson & Johnson fits Miller's criteria perfectly. It pays a 3.6% dividend that has been growing 11.1%, on average, for the past five years.
The Motley Fool August 11, 2010 David Meier	Does Bill Miller Think Abbott Laboratories Is Attractive? The company meets all the criteria above, and it could offer a 14% return over time -- although it will be hard for the company to maintain such a dividend growth rate.
The Motley Fool August 10, 2010 Jeremy Phillips	Technically, MannKind Is a Buy For MannKind, it's all about Afrezza, an inhaled insulin that attempts to succeed where other drug companies have failed.
The Motley Fool August 10, 2010 David Meier	Is USANA Health Sciences' Management Up to the Task? It certainly looks like USANA Health Sciences' management has been creating value for its shareholders.
The Motley Fool August 10, 2010 Charly Travers	Gilead Sciences' Magic Formula A simple screen for market-beating returns.
<Older 6561-6570 Newer> Return to current articles.